二二碳胺衍生物作为具有抗神经炎症活性的新型单胺氧化酶B抑制剂
Demeng Sun1, Bo Wang1, Yanmei Jiang1
1School of Bioengineering, Zhuhai Campus, Zunyi Medical University, Zhuhai 519041, China.
ACS medicinal chemistry letters
|June 19, 2024
概括
一种新型化合物,1l有效抑制人类单胺氧化酶-B (hMAO-B) 并减少神经炎症. 这种双重作用分子显示出作为神经系统疾病潜在的治疗的前景.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 人类单胺氧化酶-B (hMAO-B) 是神经退行性疾病的关键标.
- 抑制hMAO-B和神经炎症是潜在的治疗策略.
研究的目的:
- 设计,合成和评估新型N--2,3-二二子[b][1,4]二氧化-6-碳胺衍生物作为hMAO-B抑制剂.
- 为了研究这些化合物的结构-活性关系 (SAR).
- 评估最强大的抑制剂的抗神经炎症和神经保护作用.
主要方法:
- 合成N-phenyl-2,3-dihydrobenzo[b][1,4]二氧化-6-carboxamide衍生物的合成.
- 在体外酶抑制对hMAO-A和hMAO-B的测定.
- 酶动力学和可逆性研究.
- 基于细胞的测试来评估抗神经炎症和神经保护作用.
- 分子对接研究. 分子对接研究.
主要成果:
- 化合物1l显示出强大的hMAO-B抑制 (IC50 = 0.0083 μM) 具有高选择性 (>4819).
- 化合物1l作为一种竞争性和可逆的hMAO-B抑制剂.
- 化合物1l抑制了BV2细胞中的NO,TNF-α和IL-1β释放,并减弱了Aβ1-42诱导的细胞毒性.
- 分子对接提供了对酶-抑制剂相互作用的见解.
- 化合物1l表现出较低的神经毒性.
结论:
- 化合物1l是一种强效,选择性和可逆的hMAO-B抑制剂.
- 化合物1l具有抑制hMAO-B和减少神经炎症的双重治疗潜力.
- 化合物1l值得进一步研究,因为它是神经系统疾病的新.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
220
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
220
Cholinergic Antagonists: Therapeutic Uses
741
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
741
Cholinergic Antagonists: Pharmacokinetics
431
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
431
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Adrenergic Agonists: Indirect-Acting Agents
1.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.6K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K


